Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States

NCT05157087 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05157087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05157087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
March 1, 2020
Completion date
December 1, 2020
Enrollment
16,246 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

asthma